SCHEMBL455386

SCHEMBL455386

CC(C)(N)C(=O)O.CC(C)(N)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.53
TSHR P16473 3/20 0.53
GGT1 P19440 1/20 0.42
CYP2C19 P33261 2/20 0.40
CYP2D6 P10635 1/20 0.40
HIF1A Q16665 1/20 0.40
GRM2 Q14416 1/20 0.40
TP53 P04637 1/20 0.38
ARG1 P05089 1/20 0.37
ARG2 P78540 1/20 0.37
FDPS P14324 1/20 0.37
MAPT P10636 1/20 0.36
PTGS1 P23219 1/20 0.36
MEN1 O00255 1/20 0.36
CYP1A2 P05177 1/20 0.36
THRB P10828 1/20 0.36
KMT2A Q03164 1/20 0.36
BLM P54132 1/20 0.36
ACHE P22303 1/20 0.36
FFAR3 O14843 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23312 1.00
SCHEMBL29956233 1.00
SCHEMBL31421734 1.00
SCHEMBL11256487 1.00
Water SCHEMBL11216754 0.96
SCHEMBL8902015 0.96
SCHEMBL28212367 0.96
Hydrochloric Acid SCHEMBL1291178 0.96
Hydrochloric Acid SCHEMBL159297 0.96
SCHEMBL15820259 0.96

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4201951-B1 METHOD FOR PEPTIDE SYNTHESIS BACHEM HOLDING AG (CH) 2023-11-22 EP disclosed
WO-2023117904-A1 METHOD FOR PEPTIDE SYNTHESIS BACHEM HOLDING AG (CH) 2023-06-29 WO disclosed
EP-4201951-A1 METHOD FOR PEPTIDE SYNTHESIS Bachem Holding AG (CH) 2023-06-28 EP disclosed
EP-3658169-A1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER Yeda Research and Development Co. Ltd (IL) 2020-06-03 EP disclosed
WO-2019021284-A1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2019-01-31 WO disclosed
EP-3046929-A1 ERK-DERIVED PEPTIDES AND USES THEREOF Yeda Research and Development Co., Ltd. (IL) 2016-07-27 EP disclosed
CN-103649019-B Be used for the treatment of the 1-Piperazino-3-phenyl-indane of schizoid deuterate H. LUNDBECK A/S (DK) 2015-09-16 CN disclosed
WO-2015040609-A1 ERK-DERIVED PEPTIDES AND USES THEREOF YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2015-03-26 WO disclosed
CN-103649019-A Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia LUNDBECK & CO AS H 2014-03-19 CN disclosed
US-8269037-B2 Absorption medium for removing acid gases which comprises amino acid and acid promoter BASF SE (DE) 2012-09-18 US disclosed
US-20120051989-A1 REMOVAL OF ACID GASES FROM A FLUID FLOW BY MEANS OF REDUCED COABSORPTION OF HYDROCARBONS AND OXYGEN BASF SE (DE) 2012-03-01 US disclosed
US-20120034364-A1 USE OF PEPTIDES FOR IMPARTING KOKUMI AJINOMOTO CO., INC. (JP) 2012-02-09 US disclosed
EP-2415359-A1 USE OF PEPTIDE FOR IMPARTING BODY TASTE Ajinomoto Co., Inc. (JP) 2012-02-08 EP disclosed
US-8034166-B2 Carbon dioxide absorbent requiring less regeneration energy BASF SE (DE) 2011-10-11 US disclosed
US-20100186590-A1 ABSORPTION MEDIUM FOR REMOVING ACID GASES WHICH COMPRISES AMINO ACID AND ACID PROMOTER BASF SE (DE) 2010-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120034364-A1 USE OF PEPTIDES FOR IMPARTING KOKUMI GIPR, GABRA6, GABRB1 ALDH1A1 1964/4885TSHR 799/4885GGT1 657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.